Serial Number | 87365595 |
Word Mark | ALIANZO |
Filing Date | Thursday, March 9, 2017 |
Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
Status Date | Monday, October 26, 2020 |
Registration Number | 0000000 |
Registration Date | NOT AVAILABLE |
Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
Published for Opposition Date | Tuesday, July 25, 2017 |
Goods and Services | Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin; Pharmaceutical preparations used in connection with and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body |
Translation of Words in Mark | The word "ALIANZO" has no meaning in a foreign language. |
International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
US Class Codes | 006, 018, 044, 046, 051, 052 |
Class Status Code | 6 - Active |
Class Status Date | Wednesday, March 15, 2017 |
Primary Code | 005 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
Party Name | Allergan Sales, LLC |
Party Type | 20 - Owner at Publication |
Legal Entity Type | 16 - Limited Liability Company |
Address | Madison, CA 07940 |
Party Name | Allergan Sales, LLC |
Party Type | 10 - Original Applicant |
Legal Entity Type | 16 - Limited Liability Company |
Address | Irvine, CA 92612 |
Event Date | Event Description |
Monday, October 26, 2020 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
Monday, October 26, 2020 | ABANDONMENT - NO USE STATEMENT FILED |
Saturday, March 21, 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Friday, March 20, 2020 | EXTENSION 5 GRANTED |
Friday, March 13, 2020 | EXTENSION 5 FILED |
Friday, March 20, 2020 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
Friday, March 13, 2020 | TEAS EXTENSION RECEIVED |
Wednesday, September 18, 2019 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Monday, September 16, 2019 | EXTENSION 4 GRANTED |
Monday, September 16, 2019 | EXTENSION 4 FILED |
Monday, September 16, 2019 | TEAS EXTENSION RECEIVED |
Tuesday, March 5, 2019 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Friday, March 1, 2019 | EXTENSION 3 GRANTED |
Friday, March 1, 2019 | EXTENSION 3 FILED |
Friday, March 1, 2019 | TEAS EXTENSION RECEIVED |
Tuesday, September 11, 2018 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Friday, September 7, 2018 | EXTENSION 2 GRANTED |
Friday, September 7, 2018 | EXTENSION 2 FILED |
Friday, September 7, 2018 | TEAS EXTENSION RECEIVED |
Thursday, February 1, 2018 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Tuesday, January 30, 2018 | EXTENSION 1 GRANTED |
Tuesday, January 30, 2018 | EXTENSION 1 FILED |
Tuesday, January 30, 2018 | TEAS EXTENSION RECEIVED |
Tuesday, September 19, 2017 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
Tuesday, July 25, 2017 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Tuesday, July 25, 2017 | PUBLISHED FOR OPPOSITION |
Wednesday, July 5, 2017 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Wednesday, June 21, 2017 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
Tuesday, June 20, 2017 | ASSIGNED TO LIE |
Friday, May 12, 2017 | APPROVED FOR PUB - PRINCIPAL REGISTER |
Friday, May 12, 2017 | EXAMINER'S AMENDMENT ENTERED |
Friday, May 12, 2017 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
Friday, May 12, 2017 | EXAMINERS AMENDMENT E-MAILED |
Friday, May 12, 2017 | EXAMINERS AMENDMENT -WRITTEN |
Tuesday, May 9, 2017 | ASSIGNED TO EXAMINER |
Wednesday, March 15, 2017 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
Monday, March 13, 2017 | NEW APPLICATION ENTERED IN TRAM |